Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D50ESV
|
|||
| Drug Name |
Polivy
|
|||
| Synonyms |
Polatuzumab vedotin-piiq
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 2 | [1] | |
| Company |
Roche/Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell-specific glycoprotein B29 (CD79B) | Target Info | Agonist | [2] |
| KEGG Pathway | B cell receptor signaling pathway | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Leptin Signaling Pathway | ||||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||
| WikiPathways | Signaling by the B Cell Receptor (BCR) | |||
| B Cell Receptor Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04659044) Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | Polatuzumab Vedotin: First Global Approval. Drugs. 2019 Sep;79(13):1467-1475. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.